BACKGROUND: The histone deacetylase inhibitor ITF2357 has potent cytotoxic activity in multiple myeloma in vitro and has entered clinical trials for this disease. DESIGN AND METHODS: In order to gain an overall view of the activity of ITF2357 and identify specific pathways that may be modulated by the drug, we performed gene expression profiling of the KMS18 multiple myeloma cell line treated with the drug. The modulation of several genes and their biological consequence were verified in a panel of multiple myeloma cell lines and cells freshly isolated from patients by using polymerase chain reaction analysis and western blotting. RESULTS: Out of 38,500 human genes, we identified 140 and 574 up-regulated genes and 102 and 556 down-modulated genes at 2 and 6 h, respectively, with a significant presence of genes related to transcription regulation at 2 h and to cell cycling and apoptosis at 6 h. Several of the identified genes are particularly relevant to the biology of multiple myeloma and it was confirmed that ITF2357 also modulated their encoded proteins in different multiple myeloma cell lines. In particular, ITF2357 down-modulated the interleukin-6 receptor alpha (CD126) transcript and protein in both cell lines and freshly isolated patients' cells, whereas it did not significantly modify interleukin-6 receptor beta (CD130) expression. The decrease in CD126 expression was accompanied by decreased signaling by interleukin-6 receptor, as measured by STAT3 phosphorylation in the presence and absence of inter-leukin-6. Finally, the drug significantly down-modulated the MIRHG1 transcript and its associated microRNA, miR-19a and miR-19b, known to have oncogenic activity in multiple myeloma. CONCLUSIONS: ITF2357 inhibits several signaling pathways involved in myeloma cell growth and survival.
BACKGROUND: The histone deacetylase inhibitor ITF2357 has potent cytotoxic activity in multiple myeloma in vitro and has entered clinical trials for this disease. DESIGN AND METHODS: In order to gain an overall view of the activity of ITF2357 and identify specific pathways that may be modulated by the drug, we performed gene expression profiling of the KMS18 multiple myeloma cell line treated with the drug. The modulation of several genes and their biological consequence were verified in a panel of multiple myeloma cell lines and cells freshly isolated from patients by using polymerase chain reaction analysis and western blotting. RESULTS: Out of 38,500 human genes, we identified 140 and 574 up-regulated genes and 102 and 556 down-modulated genes at 2 and 6 h, respectively, with a significant presence of genes related to transcription regulation at 2 h and to cell cycling and apoptosis at 6 h. Several of the identified genes are particularly relevant to the biology of multiple myeloma and it was confirmed that ITF2357 also modulated their encoded proteins in different multiple myeloma cell lines. In particular, ITF2357 down-modulated the interleukin-6 receptor alpha (CD126) transcript and protein in both cell lines and freshly isolated patients' cells, whereas it did not significantly modify interleukin-6 receptor beta (CD130) expression. The decrease in CD126 expression was accompanied by decreased signaling by interleukin-6 receptor, as measured by STAT3 phosphorylation in the presence and absence of inter-leukin-6. Finally, the drug significantly down-modulated the MIRHG1 transcript and its associated microRNA, miR-19a and miR-19b, known to have oncogenic activity in multiple myeloma. CONCLUSIONS:ITF2357 inhibits several signaling pathways involved in myeloma cell growth and survival.
Authors: Sorin Armeanu; Anita Pathil; Sascha Venturelli; Paolo Mascagni; Thomas S Weiss; Martin Göttlicher; Michael Gregor; Ulrich M Lauer; Michael Bitzer Journal: J Hepatol Date: 2005-02 Impact factor: 25.083
Authors: Kristin Eckfeld; Luke Hesson; Michele D Vos; Ivan Bieche; Farida Latif; Geoffrey J Clark Journal: Cancer Res Date: 2004-12-01 Impact factor: 12.701
Authors: N Robillard; G Jego; C Pellat-Deceunynck; D Pineau; D Puthier; M P Mellerin; S Barillé; M J Rapp; J L Harousseau; M Amiot; R Bataille Journal: Clin Cancer Res Date: 1998-06 Impact factor: 12.531
Authors: E M Ocio; P G Richardson; S V Rajkumar; A Palumbo; M V Mateos; R Orlowski; S Kumar; S Usmani; D Roodman; R Niesvizky; H Einsele; K C Anderson; M A Dimopoulos; H Avet-Loiseau; U-H Mellqvist; I Turesson; G Merlini; R Schots; P McCarthy; L Bergsagel; C S Chim; J J Lahuerta; J Shah; A Reiman; J Mikhael; S Zweegman; S Lonial; R Comenzo; W J Chng; P Moreau; P Sonneveld; H Ludwig; B G M Durie; J F S Miguel Journal: Leukemia Date: 2013-11-20 Impact factor: 11.528
Authors: Sara Correia Marques; Maria Bach Laursen; Julie Støve Bødker; Malene Krag Kjeldsen; Steffen Falgreen; Alexander Schmitz; Martin Bøgsted; Hans Erik Johnsen; Karen Dybkaer Journal: Oncotarget Date: 2015-01-01